Claire M. Lucas
Chester, ENG CH21BR, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia.
Journal: International journal of molecular sciences
Published: January 06, 2026
Evaluating caregiver-child interactions in low- and middle-income countries: a systematic review of tools and methods.
Journal: Journal of reproductive and infant psychology
Published: March 05, 2024
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Journal: Oncogene
Published: February 21, 2023
Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
Journal: Cancers
Published: June 24, 2021
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 24, 2020
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Journal: Science translational medicine
Published: May 01, 2018
Oxygen delivery from the cerebral microvasculature to tissue is governed by a single time constant of approximately 6 seconds.
Journal: Microcirculation (New York, N.Y. : 1994)
Published: July 20, 2017
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
Journal: Leukemia
Published: August 28, 2015
Last Updated: 09/26/2026